SUMIT-ELA: Phase 1b/2 combination of cyclin-dependent kinase 7 inhibitor (CDK7i) samuraciclib and selective estrogen receptor degrader (SERD) elacestrant in advanced hormone receptor positive (HR plus ) breast cancer after CDK4/6i

被引：1

作者：

Patnaik, Amita

Novoa, Silvia Antolin

Bellet-Ezquerra, Meritxell

Bidard, Francois-Clement

Boni, Valentina

Brunet, Maxime

Campone, Mario

Garay, Carlos

Gomez-Bravo, Raquel

Howell, Sacha

Jeselsohn, Rinath

Lord, Simon

Mazzei, Paolo

De Miguel, Maria

Roesch, Erin

Stradella, Agostina

Vanacker, Helene

Vicier, Cecile

Wander, Seth

Clack, Glen

McIntosh, Stuart

机构：

来源：

关键词：

D O I：

10.1158/1538-7445.SABCS23-PO3-04-13

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PO3-04-13

引用

页数：3